|Therapeutic Class:||Anti-diarrhoeal Antimicrobial drugs, Other Anti-protozoals, Systemic Urinary Anti- infective|
|Manufacturer:||Apollo Pharmaceutical Laboratories Ltd.|
|Last Updated:||2020-11-19 18:15:00|
Apigamon Tablet contains Nalidixic Acid. Apigamon uses:
Nalidixic acid is indicated in -
Apigamon Tablet contains Nalidixic Acid 500 mg. Apigamon doses:
Infants and children 3 month of age and over:
Should be taken with food.
Gastro-intestinal disturbances including nausea, vomiting, diarrhoea, haemolysis in G6PD deficiency, allergic reaction including urticaria, rashes, fever, arthralgia, eosinophilia, also myalgia, muscle weakness, phototoxicity, jaundice, visual disturbances and convulsions.
Nalidixic acid is a synthetic narrow spectrum antibacterial. It is bacteriostatic or bactericidal depending on the concentration. Nalidixic acid appears to act by inhibiting bacterial DNA synthesis, possibly by interfering with DNA polymerization. It is rapidly and completely absorbed from the G.I. Tract. Parent drug and active metabolites are distributed to most tissues specially to the kidney and to the urine.
General: Should be used with caution in liver disease, epilepsy or severe cerebral arteriosclerosis patients. Periodic blood counts and renal and liver function tests should be performed if treatment is continued for more than 2 weeks. If bacterial resistance emerges, rapid change of drug should be made.
Children: Should not be used to infants less than 3 months of age.
Concomitant use of Nalidixic acid with melphalan there have been reports of death froms severe blood containing diarrhoea caused by hemorrhagic ulcerative colitis. Probenecids inhibits tubular secretion of nalidixic acid and may therefore elevate serum concentration, possibly enhancing toxicity. Chlorpromazine and Perphenazine have been shown to potentiate the effect of Nalidixic Acid in vitro.
Pregnancy: There is the possibility that it may cause cartilage damage and as it is a DNA-gyrase inhibitor there is a possibility of causing DNA damage too. Nalidixic acid is excreted in breast milk and there is a report of hemolytic anaemia in a breast feed child of an azotemic mother.
Nalidixic Acid is contraindicated to known hypersensitivity to Nalidixic acid, history of convulsive disorders and patients with porphyria. Should be used with caution in patients with liver and renal disease. Also in glucose 6 - phosphate dehydrogenase deficiency.
Renal Impairment: Reduced doses should be considered.
Hepatic Impairment: Reduced doses should be considered.
Symptoms: Toxic psychosis, convulsions, increased intracranial pressure, metabolic acidosis, vomiting, nausea, lethargy.
Management: Increase fluid admin; supportive measures. Anticonvulsants may be used in severe cases.
Store at room temperature, up to 25° C
Apigamon Tablet price in Bangladesh 5.53